NEW YORK (GenomeWeb News) – GeneLink today said that it has raised $2.4 million through two private placements of its stock.

The consumer genomics firm said that it closed the first placement in January and the second one on Feb. 27. According to the firm's CEO, Monte Taylor, funding came from shareholders of GeneLink, which is publicly traded on the OTC Bulletin Board, marketing affiliates of GeneWize Life Sciences, and "arms-length" financial investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.